公开(公告)号：US20100216747A1

公开(公告)日：2010-08-26

申请号：US12671414

申请日：2008-08-01

申请人： Eiji Ochiai ,  Miyuki Nishiga ,  Kenichiro Takagi ,  Yoshiaki Azuma

发明人： Eiji Ochiai ,  Miyuki Nishiga ,  Kenichiro Takagi ,  Yoshiaki Azuma

IPC分类号： A61K31/663 ,  A61K31/675 ,  A61P19/08

CPC分类号： A61K45/06 ,  A61K31/426 ,  A61K31/663 ,  A61K31/675 ,  A61K2300/00

摘要： An object of the present invention is to provide a preventive drug and a therapeutic drug for diseases caused by abnormal bone metabolism, especially osteoporosis, which is more effective than conventional drugs. Combined use of N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}-benzamidine, or a salt thereof; and at least one compound selected from the group consisting of etidronic acid, clodronic acid, pamidronic acid, tiludronic acid, risedronic acid, minodronic acid, ibandronic acid, zoledronic acid, and salts thereof can exert higher bone resorption inhibitory effect and provide a preventive effect and a therapeutic effect for diseases caused by abnormal bone metabolism, especially osteoporosis as compared with administration of the respective agents respectively.

摘要翻译： 本发明的目的是提供一种用于由异常的骨代谢引起的疾病，特别是骨质疏松症的预防药物和治疗药物，其比常规药物更有效。 合并使用N-羟基-4- {5- [4-（5-异丙基-2-甲基-1,3-噻唑-4-基）苯氧基]戊氧基} - 苄脒或其盐; 并且选自依替膦酸，氯膦酸，帕米膦酸，替鲁膦酸，利塞膦酸，米诺膦酸，伊班膦酸，唑来膦酸及其盐中的至少一种化合物可以发挥更高的骨吸收抑制作用并提供预防效果 以及与分别给予各种试剂相比，由异常骨代谢引起的疾病，特别是骨质疏松症的治疗效果。